Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Revenue of Nuvalent, Inc. (NUVL)
Revenue in 2023 (TTM): $
According to Nuvalent, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Nuvalent, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $ | $-149,492,000 | $-126,219,000 | $-126,219,000 |
| 2022 | $ | $ | $-86,108,000 | $-81,854,000 | $-73,346,000 |
| 2021 | $ | $ | $-45,817,000 | $-46,338,000 | $-46,338,000 |
| 2020 | $ | $ | $-16,905,000 | $-14,556,000 | $-14,556,000 |
| 2019 | $ | $ | $-10,358,000 | $-11,809,000 | $-11,809,000 |